<DOC>
	<DOC>NCT01638013</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of long-term administration of ASP015K in patients who have completed Phase IIb or Phase III studies.</brief_summary>
	<brief_title>A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K</brief_title>
	<detailed_description>This study is an extension study conducted as an open-label multicenter study in rheumatoid arthritis (RA) patients who completed the Phase IIb Study of ASP015K [015K-CL-RAJ1 (hereinafter referred to as study RAJ1)], Phase III Study of ASP015K [015K-CL-RAJ3 (RAJ3)], or Phase III Study of ASP015K [015K-CL-RAJ4 (RAJ4)]. Patients will receive oral ASP015K once daily (QD) after breakfast. The ASP015K dose can be increased later if the subjects have no safety problems but show lack of efficacy. The duration of treatment with the study drug will differ depending upon the subject.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Subject has completed treatment with the study drug in studies RAJ1, RAJ3 or RAJ4 as specified in the protocol The subject himself/herself wishes to continue taking the study drug, and the investigator or subinvestigator deems continued administration to be necessary or appropriate Subject has developed an adverse reaction to the study drug in studies RAJ1, RAJ3 or RAJ4, and the risks of continuing treatment with this drug are expected to outweigh the benefits There were abnormal findings in the xray taken at Week 0, and an acute or chronic infection, tuberculosis infection, or malignancy is suspected Hepatitis B virus or hepatitis C virus carrier or has a history of a positive test for human immunodeficiency virus (HIV) infection Subject has concurrent autoimmune disease (except Sjogren's syndrome) other than RA or a history of it Subject has a clinically significant infection or disease (requiring hospitalization or parenteral therapy) Subject has QTc &lt; 300 msec on ECG measurements performed at the study site at Week 52 of studies RAJ3 or RAJ4 and has QTc &lt; 300 msec at retest.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>ASP015K</keyword>
</DOC>